CPHINYSEPharmaceutical PreparationsFiscal year ends December 31
CHINA PHARMA HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.69−0.02 (-3.49%)
Close on Oct 19, 2026
- Market cap
- $27.76M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
-3.2%−21.2 pts over 5 years
Operating margin
-78.2%−54.4 pts over 5 years
Net margin
-76.9%−50.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -8.5% | -20.0% | -17.5% | -14.7% | |
| Free cash flow | – | – | – | -31.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -14.0% | -33.3% | -20.9% | |
| Return on assets | -10.5% | -13.2% | -13.9% | |
| Current ratio | 1.68 | 0.47 | 0.32 | |
| Interest coverage | -9.6× | -8.8× | -118.8× | |
| Inventory turnover | 1.5× | 2.4× | 2.2× | |
| Capex to revenue | 1.2% | 8.0% | 1.4% | |
| Diluted shares | 1M | 1M | 4M |
Where the cash went
Fiscal 2021 to 2025, five years combined
China Pharma generated $1.91M from operations and spent $949.27K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.91M
Used
$949.27K
Capital expenditure$949.27K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-76.9%
×Asset turnover0.18×
×Equity multiplier1.51×
=Return on equity, FY2025-20.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -76.9% | 0.18× | 1.51× | -20.9% |
| FY2024 | -104.6% | 0.29× | 2.06× | -62.3% |
| FY2023 | -43.9% | 0.41× | 2.92× | -52.4% |
| FY2022 | -49.0% | 0.40× | 3.92× | -77.1% |
| FY2021 | -35.3% | 0.44× | 3.12× | -48.5% |
| FY2020 | -26.4% | 0.50× | 2.51× | -33.3% |
| FY2019 | -189.5% | 0.32× | 1.71× | -105.0% |
| FY2018 | -87.2% | 0.23× | 1.44× | -29.3% |
| FY2017 | -145.9% | 0.19× | 1.36× | -37.8% |
| FY2016 | -59.0% | 0.18× | 1.33× | -14.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$3.19M
- Cash generatingOperating cash flow above zero$148.26K
- Return on assets improvedROA up on the prior year-28.8% → -21.4%
- Earnings backed by cashOperating cash flow above net income$148.26K vs -$3.19M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.65 → 0.32
- No dilutionShare count did not rise2M → 4M
- Gross margin improvedGross margin up on the prior year-43.84% → -3.18%
- More efficientAsset turnover rose0.27 → 0.28